focus -WSS

focus

author：leisure time 2025-08-23 18:38:56 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Illumina to lay off 10% of research and development team

Wikipedia

entertainment

WSS

Supreme Court strikes down Biden student loan forgiveness program

Ukrainian soldiers say they owe lives to US

House transparency, PBM reform bill gains bipartisan support

Humana sues Biden admin over Medicare Advantage audit rule

Illumina to lay off 10% of research and development team

House transparency, PBM reform bill gains bipartisan support

Wikipedia

focus

entertainment

Hollywood unions extend contract negotiations for actors

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Activists slam private health insurers over coverage restrictions

The strange history of BMI, the body mass index

Sports medicine is finally prioritizing gender equality

ADA: All diabetes patients should be screened for liver condition

ChatGPT in medicine: STAT answers readers' burning questions

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

leisure time

The simple reason for the increase in autism diagnosis

NIH nominee Bertagnolli will get October confirmation hearing

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Illumina names Agilent executive as new CEO

Medical experts exlpore how to eliminate bias in clinical algorithms

Crinetics acromegaly drug succeeds in late

hotspot

Wikipedia

entertainment

hotspot